Paper Details

  1. Home
  2. Paper Details

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.

Author: DuezHélène, DzavikVladimir, FiévetCatherine, FruchartJean-Charles, GinesteRomain, GonzalezFrank J, HelleboidStéphane, LefebvreBruno, LefebvrePhilippe, LucGérald, PercevaultFrédéric, PetersJeffrey M, PoulainPhilippe, StaelsBart, TorraInés Pineda

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fenofibrate (FF) and gemfibrozil (GF) have similar effects on HDL cholesterol levels, but only FF increased plasma apoA-I levels. This difference may be due to FF behaving as a full agonist of PPARalpha, while GF acts as a partial agonist.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I. METHODS AND RESULTS: In a head-to-head double-blind clinical trial, both FF and GF decreased tri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/01.ATV.0000154140.73570.00

データ提供：米国国立医学図書館（NLM）

Gemfibrozil and Fenofibrate: Exploring the Fine Line in PPARalpha Modulation

Fibrates, a class of drugs used to lower cholesterol levels, exert their effects through the peroxisome proliferator-activated receptor alpha (PPARalpha). This research investigates the specific effects of two commonly used fibrates, fenofibrate (FF) and gemfibrozil (GF), on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I, highlighting the subtle differences in their mechanisms of action.

A Tale of Two Fibrates: Unraveling the Subtleties of PPARalpha Activation

The study reveals that FF and GF, while both effective in lowering triglycerides and increasing HDL cholesterol levels, exhibit distinct effects on apoA-I. FF effectively increased apoA-I levels, whereas GF did not. The study further demonstrates that PPARalpha mediates the effects of these fibrates on HDL, highlighting the importance of understanding the specific mechanisms of PPARalpha activation by different fibrates.

Balancing the Effects: Considerations for Cholesterol Management

This research provides valuable insights into the specific mechanisms of action of different fibrates, suggesting that FF may be a more effective option for increasing apoA-I levels, while GF may be a more selective PPARalpha agonist. The study emphasizes the importance of understanding the nuanced effects of different medications in the context of cholesterol management, highlighting the need for personalized treatment plans tailored to individual patient needs.

Dr.Camel's Conclusion

This research is like a desert landscape, where seemingly similar dunes hold subtle differences in their composition. Just as different dunes reflect varying shades of sand and textures, the study reveals the nuanced differences in the effects of FF and GF on PPARalpha. This research underscores the importance of understanding these subtle variations to optimize treatment approaches and achieve the best possible outcomes for patients.

Date :
  1. Date Completed 2005-11-08
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15618549

DOI: Digital Object Identifier

10.1161/01.ATV.0000154140.73570.00

Related Literature

Article Analysis
・Effects of fenofibrate・Effects of ethosuximide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.